Outlook Therapeutics has seen its analyst consensus price target increase from $1.90 to $2.80, driven by promising Phase III trial results for its eye disease drug ONS-5010 and strategic partnerships. The company is expected to beat upcoming quarterly earnings estimates, which could further boost investor confidence. Despite some cautious views, overall sentiment reflects growing optimism about the company's future performance in the biopharmaceutical sector.
Clearpool announced plans to expand its institutional lending products to the XRP Ledger (XRPL) by replacing its current token, CPOOL, with a new token called CLEAR through a 1:1 migration. This move aims to recapitalize its treasury to fund incentiv...
Meteora's native token, MET, surged 18% following reward campaigns that incentivized staking and liquidity provision. The protocol generated $20.3 million in fees over 30 days, with strong user engagement shown by a rise of over 40,000 active address...
MKDWELL surged nearly 52% after disclosing its acquisition of Landvision Inc., an AI smart-home company, despite shareholder dilution. ACV Auctions rose over 44% following its $1.9 billion acquisition agreement by Copart, Inc. Frequency Electronics j...
Kahn Swick & Foti, LLC (KSF) has launched an investigation into Sable Offshore Corp following a court order that temporarily halted the company's oil transportation through the Las Flores Pipeline. The order stems from environmental lawsuits and has ...
Several U.S.-listed stocks saw significant drops on Friday, led by the Daily Target 2X Long OKLO ETF (OKLL), which fell 18.38% due to amplified losses in Oklo Inc. shares. CPI Card Group (PMTS) declined 16.48% following a discounted secondary share o...
